Upcoming events – Pfizer's abrocitinib and Myovant's relugolix
Pfizer's abrocitinib heads against Dupixent in atopic dermatitis, while Myovant hopes to raise its Spirits.
Upcoming events – Karyopharm's myeloma expansion and Pfizer's biz dev nous
Karyopharm hopes to move Xpovio earlier in the multiple myeloma treatment sequence, and data are due for Akcea/Ionis’s triglyceride regulator, for which Pfizer paid a…
Go or no go? Enhertu’s destiny revealed and FDA decisions due for Epizyme, Novo
Enhertu gets an early thumbs up from the FDA – now decisions are due for Epizyme’s tazemetostat and Novo Nordisk's Rybelsus and Ozempic.
Upcoming events – TG's long-awaited outcome and Insmed's mid-stage lung data
After making investors wait more than a year, TG Therapeutics is gearing up to release results of its lead leukaemia combo, while Insmed hopes to succeed in a very tricky…
Upcoming events – Axsome’s depression data and Lilly’s IL-10 in lung cancer
Axsome hopes to end 2019 on a high with its depression drug AXS-05 while Lilly’s pegilodecakin is unlikely to redeem itself in lung cancer.
Ash 2019 winners and losers
Data and M&A lifts buoyant biopharma companies from Fate Therapeutics to Rocket, though on share price gain Forty Seven wins Ash 2019.
SABCS 2019 – Tecentriq stumbles in triple negative disease
Disappointing data in a small neoadjuvant trial testing Tecentriq in triple negative breast cancer suggests that once again Keytruda may have an edge.
SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance
New data confirms that trastuzumab deruxtecan has an exciting destiny, but the antibody-drug conjugate’s impressive efficacy in late-stage breast cancer comes at a price.
Ash 2019 – Regeneron takes the bispecific baton and runs
Regeneron and Xencor add to the growing evidence backing bispecifics in certain lymphomas, a space that looks set to become fiercely competitive.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.